BetterLife Pharma Company Description

BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada.

It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections.

The company’s products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders.

It is also developing MM-003, which has completed Phase II clinical trials for the treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream that has completed Phase II clinical trials for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia.

The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019.

BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

BetterLife Pharma Inc.

Country	Canada
Founded	2002
Industry	Biotechnology
Sector	Healthcare
Employees	7
CEO	Ahmad Doroudian

Contact Details

Address: 1275 West 6th Avenue Vancouver, British Columbia V6H 1A6 Canada
Website	abetterlifepharma.com

Stock Details

Ticker Symbol	BETR
Exchange	Canadian Securities Exchange
Stock Type	Common Stock
Fiscal Year	February - January
Reporting Currency	CAD
ISIN Number	CA08772P2026
SIC Code	2836

Key Executives

Name	Position
Dr. Ahmad Doroudian Ph.D.	Founder, Chief Executive Officer and Chairman
Moira Ong C.A., CPA, CA, CFA	Chief Financial Officer
Dr. Hooshmand Sheshbaradaran Ph.D.	Chief Operating Officer
Dr. Stephen Sangha	Corporate Development Advisor and Director
Scott Rudge Ph.D.	Head of CMC